FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I-C-i) or pharmaceutically acceptable salts thereof. In formula (I-C-i), R1 is C1-6 alkyl and R2 is -CH2CF3, ethyl, isopropyl or cyclopropyl. Invention also relates to a pharmaceutical composition and a method for positive allosteric modulation of the NMDA receptor.
EFFECT: obtaining novel compounds of formula (I-C-i), which have the property of a positive allosteric NMDA modulator and can be used in treating NMDA-mediated disorders.
17 cl, 1 tbl, 39 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
OXYSTEROLES AND METHODS OF USING THEM | 2016 |
|
RU2744267C2 |
BORON-CONTAINING PDE4 INHIBITORS | 2019 |
|
RU2793936C2 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | 2015 |
|
RU2699359C2 |
NEUROACTIVE STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2808166C2 |
NEUROACTIVE STEROIDS AND METHODS FOR USE THEREOF | 2014 |
|
RU2684103C2 |
COMPOSITIONS SUITABLE FOR TREATING DISORDERS ASSOCIATED WITH KIT | 2014 |
|
RU2706235C2 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
Authors
Dates
2021-02-04—Published
2016-07-06—Filed